Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash from Financing Activities (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Cash from Financing Activities for 9 consecutive years, with -$34000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Financing Activities fell 1600.0% year-over-year to -$34000.0, compared with a TTM value of -$255000.0 through Jun 2025, down 100.31%, and an annual FY2025 reading of -$143000.0, down 1.42% over the prior year.
  • Cash from Financing Activities was -$34000.0 for Q2 2025 at VYNE Therapeutics, up from -$87000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $82.7 million in Q4 2023 and bottomed at -$33.6 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $6.9 million, with a median of -$30000.0 recorded in 2022.
  • Peak annual rise in Cash from Financing Activities hit 52402.14% in 2021, while the deepest fall reached 41025.61% in 2021.
  • Year by year, Cash from Financing Activities stood at -$38000.0 in 2021, then skyrocketed by 647.37% to $208000.0 in 2022, then soared by 39641.83% to $82.7 million in 2023, then crashed by 100.16% to -$132000.0 in 2024, then soared by 74.24% to -$34000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for VYNE at -$34000.0 in Q2 2025, -$87000.0 in Q1 2025, and -$132000.0 in Q4 2024.